Filtered By:
Source: The American Journal of Cardiology
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 715 results found since Jan 2013.
Effect of Near Monopoly in the Left Ventricular Assist Device Market
In 2001, the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart (REMATCH) trial changed the trajectory of the treatment of heart failure when results revealed a clinically meaningful survival benefit and an improved quality of life in patients with the HeartMate XVE left ventricular assist device (LVAD).1 Nearly 2 decades later, LVADs evolved and the results of the ENDURANCE trial revealed that 2 continuous-flow LVADs were noninferior to each other. The HeartWare LVAD (HVAD) was associated with a higher risk of stroke, whereas the use of the HeartMate II (HM2) was associated with more freq...
Source: The American Journal of Cardiology - October 24, 2021 Category: Cardiology Authors: Amit Alam Source Type: research
Ischemic and Bleeding Events After First Major Bleeding Event in Patients Undergoing Coronary Stent Implantation
There is a scarcity of data on ischemic and bleeding events in patients who experienced major bleeding after percutaneous coronary intervention (PCI). Moreover, there also is a shortage of data on comparative outcomes between patients with and without interruption of an antithrombotic drug after major bleeding. We evaluated the incidence and prognostic impacts of ischemic (myocardial infarction or ischemic stroke) and bleeding (Bleeding Academic Research Consortium type 3 or 5) events after major bleeding in 12,691 consecutive patients who underwent first PCI in the Coronary Revascularization Demonstrating Outcome Study in...
Source: The American Journal of Cardiology - October 24, 2021 Category: Cardiology Authors: Ko Yamamoto, Masahiro Natsuaki, Takeshi Morimoto, Hiroki Shiomi, Yusuke Yoshikawa, Junichi Tazaki, Takeshi Tada, Hirotoshi Watanabe, Eri Kato, Mamoru Toyofuku, Tsukasa Inada, Kazuhisa Kaneda, Teruki Takeda, Hiroshi Sakai, Takashi Yamamoto, Hiroshi Eizawa, Source Type: research
Prevention and Treatment of Atrial Fibrillation via Risk Factor Modification
Atrial fibrillation (AF) is the most common clinically significant arrhythmia, and it increases stroke risk. A preventive approach to AF is needed because virtually all treatments such as cardioversion, antiarrhythmic drugs, ablation, and anticoagulation are associated with high cost and carry significant risk. A systematic review was performed to identify effective lifestyle-based strategies for reducing primary and secondary AF. A PubMed search was performed using articles up to March 1, 2021.
Source: The American Journal of Cardiology - September 25, 2021 Category: Cardiology Authors: Evan L. O'Keefe, Jessica E. Sturgess, James H. O'Keefe, Sanjaya Gupta, Carl J. Lavie Source Type: research
Comparison of Low and Full Dose Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Renal Dysfunction (from a National Registry)
The use of direct oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) is robust. However, the efficacy and safety of different dosage in patients with renal dysfunction is still a clinical challenge. We aimed to evaluate the clinical characteristics and outcomes of patients treated with apixaban in its different doses. A multicenter prospective cohort study, where consecutive eligible apixaban or warfarin treated patients with NVAF and renal impairment, were registered.
Source: The American Journal of Cardiology - September 7, 2021 Category: Cardiology Authors: Chen Gurevitz, Ela Giladi, Alon Barsheshet, Robert Klempfner, Ilan Goldenberg, Ran Kornowski, Avishay Elis Source Type: research
Impact of Embolic Protection Device Placed During Transcatheter Aortic Valve Implantation on Postdischarge Stroke Prevention
We extracted data from the Nationwide Readmission Database (NRD) from 2016 to 2018. We identified 165,100 index patients who underwent tanscatheter aortic valve implantation (TAVI) using International Classification of Disease-10-Procedural Codes (ICD-10-PCS) 02RF3x, X2RF332, and X2RF432. We used ICD-10-PCS code X2A5312 to identify 3,672 patients who had concurrent utilization of embolic protection device (EPD). We excluded patients with ages
Source: The American Journal of Cardiology - August 28, 2021 Category: Cardiology Authors: Monil Majmundar, Ashish Kumar, Ankur Kalra Source Type: research
Meta-Analysis Addressing the Effect of Mineralcorticoid Receptor Antagonists on the Risk for New-Onset Atrial Fibrillation
Atrial fibrillation (AF) constitutes the most common, major cardiac arrhythmia worldwide, with an estimated prevalence in the United States equal to 2.3 million affected subjects, projected to increase to 5.6 million by 2050.1 Hypertension and background heart disease (mainly, congestive heart failure) or valve disease represent main risk factors for AF development.1 Other modifiable risk factors are sedentary lifestyle, smoking, obesity, diabetes mellitus, and obstructive sleep apnea.2 AF is associated with a significant increase in the risk for all-cause and cardiovascular death, ischemic stroke, heart failure (HF), isch...
Source: The American Journal of Cardiology - August 13, 2021 Category: Cardiology Authors: Dimitrios Patoulias, Christodoulos Papadopoulos, Maria Toumpourleka, Michael Doumas Source Type: research
Risk of Ischemic Stroke in Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Patients With Prior Stroke
It has not been well studied whether transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR) have lower risk of ischemic stroke (IS) in those with prior history of IS. From the Nationwide Readmission Database from October 2015 to November 2017, TAVI and SAVR above age 50 were identified with the International Classification of Diseases, Tenth Revision, Clinical Modification/Procedure Coding System codes. Transapical TAVI and SAVR with concomitant bypass, mitral, or tricuspid surgery were excluded.
Source: The American Journal of Cardiology - August 6, 2021 Category: Cardiology Authors: Tomo Ando, Said Ashraf, Alexandros Briasoulis, Hisato Takagi, Cindy L. Grines, Aaqib H. Malik Tags: Valvular Heart Disease Source Type: research
Meta-analysis of Surgical Left Atrial Appendage Occlusion During Cardiac Surgery
Atrial fibrillation (AF) is a common arrhythmia in the elderly population and represents a significant risk for cardio-embolic stroke secondary to thrombi originating from the left atrial appendage.1,2 Although oral anticoagulation is considered the standard of care, numerous concerns exist. Patient noncompliance, intolerance, and subtherapeutic drug levels are examples.3 Moreover, the risk of bleeding poses a significant problem, especially in elderly, frail patients. Surgical-left atrial appendage occlusion (S-LAAO) has been considered an alternative strategy to reduce the risk of future cardioembolic events.
Source: The American Journal of Cardiology - July 24, 2021 Category: Cardiology Authors: Mohamed M.G. Mohamed, Mohammed Faisaluddin, Babikir Kheiri, Mohammed Osman Source Type: research
The CHA2DS2-VASc Score for Risk Stratification of Stroke in Heart Failure With-vs-Without Atrial Fibrillation
A recent study suggested that the CHA2DS2-VASc score can risk stratify heart failure (HF) patients without atrial fibrillation (AF) for stroke. We performed a retrospective analysis using the national Veteran Affairs database to externally validate the findings. Crude incidence rates of end points were calculated. A Cox proportional model was used to study the association between the CHA2DS2-VASc score and outcomes. In HF patients with AF (n = 17,481) and without AF (n = 36,935), the 1 year incidence rate for ischemic stroke, thromboembolism, thromboembolism (without MI), and death were 2.7 and 2.0%; 10.3 and 7.9%; 4....
Source: The American Journal of Cardiology - July 14, 2021 Category: Cardiology Authors: George R. Marzouka, Harold Rivner, Vijay Mehta, Juan Lopez, Igor Vaz, Fei Tang, Hemant Ishwaran, Jeffrey J. Goldberger Source Type: research
Usefulness of Glucagon-Like Peptide-1 Receptor Agonists to Reduce Adverse Cardiovascular Disease Events in Patients with Type 2 Diabetes Mellitus
The objective of this study was to analyze randomized controlled trials (RCT) testing GLP-1 RA's effect on CVD events among participants with type 2 diabetes (T2DM). RCTs comparing GLP-1 RA versus placebo were identified using the PubMed and Cochrane databases. The endpoints in this study included major adverse cardiovascular events (MACE; a composite of cardiovascular death, nonfatal myocardial infarction (MI), and nonfatal stroke), and the individual components of MACE.
Source: The American Journal of Cardiology - July 12, 2021 Category: Cardiology Authors: Simran Grewal, Ninad Zaman, Louis Borgatta, Matthew Nudy, Andrew J. Foy, Brandon Peterson Source Type: research
Meta-Analysis of Usefulness of Antiplatelet Therapy in Ischemic Stroke or Transient Ischemic Attack
The efficacy of early administration of dual antiplatelet therapy (DAPT) for secondary prevention after acute ischemic stroke or transient ischemic attack (TIA) is uncertain. This systematic review and meta-analysis compares the safety and efficacy of early administration (
Source: The American Journal of Cardiology - July 2, 2021 Category: Cardiology Authors: Giorgio A. Medranda, Cheng Zhang, Gheorghe Doros, Charan Yerasi, Brian C. Case, William S. Weintraub, Ron Waksman Source Type: research
Using Thoracic Artery Calcium Score to Predict Stroke
We are very enthused about the concept presented by Obisesan et al.1 regarding the use of thoracic artery calcium (TAC) as a predictor of stroke mortality. The logic on why aortic atherosclerosis is more closely related (to stroke mortality) than coronary artery calcification (CAC) scores is intriguing – we initially expected it to run in parallel but the explanation they give makes good sense. We also really appreciate the practicality – that it can be done easily with the data already acquired.
Source: The American Journal of Cardiology - June 17, 2021 Category: Cardiology Authors: Joseph C. Lee, Sushil Allen Luis, Alaa Alghamry Source Type: research
Meta-Analysis of Racial Disparity in Utilization of Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation
Atrial fibrillation (AF) is the most common arrhythmia in the United States (US), and is associated with a substantial increase in the risk of ischemic stroke. Although prevalence of AF is lower in black individuals, they face a higher risk of stroke compared with patients of white race.1 Oral anticoagulant (OAC) therapy is the stroke prevention strategy in high-risk patients with AF. Despite the higher burden of ischemic stroke in Black AF patients, some studies suggest lower utilization of OAC among them.
Source: The American Journal of Cardiology - June 17, 2021 Category: Cardiology Authors: Izza Shahid, Muhammad Shariq Usman, Tariq Jamal Siddiqi, Faiza Zakaria, Mohamad Alkhouli Source Type: research
Trends in Cerebral Embolic Protection Device Use and Association With Stroke Following Transcatheter Aortic Valve Implantation
Stroke remains a serious complication of transcatheter aortic valve implantation (TAVI). Prior studies examining the association between cerebral embolic protection device (CEPD) use and stroke following TAVI have produced conflicting results. We used the Nationwide Readmissions Databases to identify all percutaneous (non-transapical) TAVIs performed in the US from July, 2017 to December, 2018. Overlap propensity score weighted logistic regression models were used to determine the association between CEPD use and outcomes.
Source: The American Journal of Cardiology - June 17, 2021 Category: Cardiology Authors: Dhaval Kolte, Sahil Khera, Salik Nazir, Neel M. Butala, Deepak L. Bhatt, Sammy Elmariah Source Type: research
Relation of Serum Uric Acid and Cardiovascular Events in Adults Aged 20-49 Years
In this study, we aimed to identify the association of medication na ïve SUA with incident CVD including myocardial infarction (MI), stroke, heart failure (HF) and atrial fibrillation (AF) using a nationwide epidemiological database. We analyzed 353,613 participants aged 20–49 years, who were not taking uric acid lowering medications, and had no prevalent history of cardiovascular disease (CVD) using a nationwide health claims database collected in the JMDC Claims Database between 2005 and 2018.
Source: The American Journal of Cardiology - June 14, 2021 Category: Cardiology Authors: Hikari Seki, Hidehiro Kaneko, Hiroyuki Morita, Hidetaka Itoh, Kojiro Morita, Satoshi Matsuoka, Hiroyuki Kiriyama, Tatsuya Kamon, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Yuichiro Yano, Sunao Nakamura, Koichi Node, Hideo Yasunaga, I Tags: Miscellaneous Source Type: research
